Abstract
The in vitro stability and metabolism of GEM[91, a 25mer phosphorothioate antisense oligonucleotide complementary to the gag mRNA region of HIV-1, was investigated using capillary electrophoresis (CE). The in vitro degradation of the parent compound at 37 degrees C was followed over the course of 120 h in human plasma. A CE method using laser-induced fluorescence detection was able to detect 5'-end intact metabolites including the parent compound extracted from biological fluids. Because the primary metabolic pathway is believed to be via 3'-exonuclease activity, the results of this study were compared with the stability of the compound in a solution containing 3'-exonuclease. The numerical solution of sequential first-order reactions was used to obtain kinetic parameters. Exonuclease digestion of the parent compound, as measured using an automated CE-UV instrument, yielded striking similarities between the two in vitro systems as well as between in vitro and in vivo systems.
Full Text
The Full Text of this article is available as a PDF (112.5 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996 Oct;14(10):376–387. doi: 10.1016/0167-7799(96)10053-6. [DOI] [PubMed] [Google Scholar]
- Cohen A. S., Bourque A. J., Wang B. H., Smisek D. L., Belenky A. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev. 1997 Feb;7(1):13–22. doi: 10.1089/oli.1.1997.7.13. [DOI] [PubMed] [Google Scholar]
- Crooke S. T., Graham M. J., Zuckerman J. E., Brooks D., Conklin B. S., Cummins L. L., Greig M. J., Guinosso C. J., Kornbrust D., Manoharan M. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther. 1996 May;277(2):923–937. [PubMed] [Google Scholar]
- Frey P. A., Sammons R. D. Bond order and charge localization in nucleoside phosphorothioates. Science. 1985 May 3;228(4699):541–545. doi: 10.1126/science.2984773. [DOI] [PubMed] [Google Scholar]
- Srinivasan S. K., Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal. 1995;9(2):129–137. doi: 10.1002/jcla.1860090210. [DOI] [PubMed] [Google Scholar]
- Zamecnik P. C., Goodchild J., Taguchi Y., Sarin P. S. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4143–4146. doi: 10.1073/pnas.83.12.4143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zamecnik P. C., Stephenson M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1978 Jan;75(1):280–284. doi: 10.1073/pnas.75.1.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang R., Diasio R. B., Lu Z., Liu T., Jiang Z., Galbraith W. M., Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol. 1995 Mar 30;49(7):929–939. doi: 10.1016/0006-2952(95)00010-w. [DOI] [PubMed] [Google Scholar]
- Zhang R., Yan J., Shahinian H. K., Shahinian H., Amin G., Lu Z., Liu T., Saag M. S., Jiang Z., Temsamani J. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther. 1995 Jul;58(1):44–53. doi: 10.1016/0009-9236(95)90071-3. [DOI] [PubMed] [Google Scholar]